Russia’s Pharmasynthez Forecasts 50% Growth To $150 Million By 2015
This article was originally published in PharmAsia News
Pharmasynthez, a Russian drug maker that acts as an intermediary between Indian and Russian drug firms, eyes a 50% increase in business by 2015, to $150 million.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.